$SUPN
SUPERNUS PHARMACEUTICALS, INC.

2013 Q1 Form 10-K Financial Statement

#000104746913002844 Filed on March 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 2011 Q4
Revenue $147.0K $1.480M $42.00K
YoY Change -29.33% 84.31% -99.13%
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $100.0K $1.500M
YoY Change 87.5%
Gross Profit Margin 68.03% 101.35%
Selling, General & Admin $13.53M $20.13M $2.800M
YoY Change 396.08% 153.94% 64.71%
% of Gross Profit 13533.0% 1342.13%
Research & Development $4.522M $23.52M $7.500M
YoY Change -15.6% -23.21% -17.58%
% of Gross Profit 4522.0% 1567.8%
Depreciation & Amortization $162.0K $871.0K $200.0K
YoY Change -28.0% -0.91% -33.33%
% of Gross Profit 162.0% 58.07%
Operating Expenses $18.06M $43.65M $10.30M
YoY Change 123.29% 13.21% -4.63%
Operating Profit -$17.91M -$42.17M
YoY Change 127.32% 11.7%
Interest Expense $727.0K $3.575M -$500.0K
YoY Change -24.43% 91.59% -83.87%
% of Operating Profit
Other Income/Expense, Net -$506.0K -$4.115M $100.0K
YoY Change -63.83% 139.52% -80.0%
Pretax Income -$18.40M -$46.28M -$10.70M
YoY Change 97.85% 17.26% 24.42%
Income Tax $0.00 $0.00 -$16.20M
% Of Pretax Income
Net Earnings -$18.41M -$46.28M $81.98M
YoY Change 98.49% -186.01% -1053.2%
Net Earnings / Revenue -12526.53% -3127.3% 195178.57%
Basic Earnings Per Share
Diluted Earnings Per Share -$595.5K -$2.661M $3.431M
COMMON SHARES
Basic Shares Outstanding 30.89M shares 17.44M shares
Diluted Shares Outstanding 17.44M shares

Balance Sheet

Concept 2013 Q1 2012 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.90M $88.50M $48.50M
YoY Change 86.9% 82.47% 48.32%
Cash & Equivalents $18.91M $40.30M $48.54M
Short-Term Investments $51.00M $48.20M $0.00
Other Short-Term Assets $1.000M $1.100M $900.0K
YoY Change 0.0% 22.22% -87.14%
Inventory $3.113M $1.200M
Prepaid Expenses
Receivables $1.650M $0.00 $128.0K
Other Receivables $600.0K $700.0K $0.00
Total Short-Term Assets $76.33M $91.50M $49.40M
YoY Change 98.69% 85.22% 24.12%
LONG-TERM ASSETS
Property, Plant & Equipment $1.687M $1.400M $1.310M
YoY Change 40.58% 7.69% 9.17%
Goodwill
YoY Change
Intangibles $626.0K $912.0K
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $363.0K $400.0K $55.00K
YoY Change -86.56% -80.95% -98.85%
Total Long-Term Assets $2.729M $2.500M $4.331M
YoY Change -42.97% -41.86% -39.85%
TOTAL ASSETS
Total Short-Term Assets $76.33M $91.50M $49.40M
Total Long-Term Assets $2.729M $2.500M $4.331M
Total Assets $79.06M $94.00M $53.73M
YoY Change 83.0% 75.05% 14.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.700M $8.000M $10.10M
YoY Change -60.22% 220.0% -10.62%
Accrued Expenses $7.240M $2.700M $9.275M
YoY Change 503.33% -70.97% 562.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.10M $11.80M $6.800M
YoY Change 31.52% 73.53%
Total Short-Term Liabilities $27.01M $23.00M $18.77M
YoY Change 35.64% 22.34% 23.49%
LONG-TERM LIABILITIES
Long-Term Debt $8.000M $11.10M $22.70M
YoY Change -59.8% -51.1%
Other Long-Term Liabilities $1.860M $2.300M $1.399M
YoY Change -40.0% -17.86% -98.16%
Total Long-Term Liabilities $1.860M $13.40M $1.399M
YoY Change -91.91% -47.45% -98.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.01M $23.00M $18.77M
Total Long-Term Liabilities $1.860M $13.40M $1.399M
Total Liabilities $37.79M $36.40M $44.29M
YoY Change -11.97% -17.83% -51.49%
SHAREHOLDERS EQUITY
Retained Earnings -$104.7M -$39.97M
YoY Change
Common Stock $31.00K $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.27M $57.60M $9.443M
YoY Change
Total Liabilities & Shareholders Equity $79.06M $94.00M $53.73M
YoY Change 83.0% 75.05% 14.32%

Cashflow Statement

Concept 2013 Q1 2012 2011 Q4
OPERATING ACTIVITIES
Net Income -$18.41M -$46.28M $81.98M
YoY Change 98.49% -186.01% -1053.2%
Depreciation, Depletion And Amortization $162.0K $871.0K $200.0K
YoY Change -28.0% -0.91% -33.33%
Cash From Operating Activities -$17.22M -$47.20M -$8.300M
YoY Change 71.07% 30.44% -29.06%
INVESTING ACTIVITIES
Capital Expenditures $372.0K $753.0K -$200.0K
YoY Change 830.0% 9.93%
Acquisitions
YoY Change
Other Investing Activities -$2.800M -$48.20M $25.60M
YoY Change -86.98% -239.31% 122.61%
Cash From Investing Activities -$3.149M -$48.96M $25.40M
YoY Change -85.39% -244.41% 120.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.936M $100.7M
YoY Change 3851.02% 347262.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$1.021M $87.92M 14.90M
YoY Change -3.41% 224.57% -1246.15%
NET CHANGE
Cash From Operating Activities -$17.22M -$47.20M -8.300M
Cash From Investing Activities -$3.149M -$48.96M 25.40M
Cash From Financing Activities -$1.021M $87.92M 14.90M
Net Change In Cash -$21.39M -$8.242M 32.00M
YoY Change -34.53% -133.23% -2233.33%
FREE CASH FLOW
Cash From Operating Activities -$17.22M -$47.20M -$8.300M
Capital Expenditures $372.0K $753.0K -$200.0K
Free Cash Flow -$17.60M -$47.95M -$8.100M
YoY Change 74.07% 30.06% -30.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011 us-gaap Debt Instrument Increase Additional Borrowings
DebtInstrumentIncreaseAdditionalBorrowings
30000000 USD
CY2011 supn Disposal Group Including Discontinued Operation Sales Consideration Cash Payment
DisposalGroupIncludingDiscontinuedOperationSalesConsiderationCashPayment
27000000 USD
CY2011 supn Disposal Group Including Discontinued Operation Contingent Consideration Milestone Payments
DisposalGroupIncludingDiscontinuedOperationContingentConsiderationMilestonePayments
3000000 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100735000 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
57000 USD
CY2011Q4 supn Deferred Tax Assets Tax Deferred Expenses Deferred Financing Costs
DeferredTaxAssetsTaxDeferredExpensesDeferredFinancingCosts
35000 USD
CY2011Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
98000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
396000 USD
CY2010 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2142000 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2155000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2487000 USD
CY2010 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16144000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
190000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
129000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1267000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
857000 USD
CY2011 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
93300000 USD
CY2011 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
36800000 USD
CY2012Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
80800000 USD
CY2012Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3900000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14809000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32714000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
514000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
477000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
48000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
60000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
282000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5018000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3901000 USD
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
788000 USD
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20531000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38222000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20531000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38222000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
752000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
452000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
190000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
110000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
-64000 USD
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
642000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
688000 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS INC
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001356576
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30892070 shares
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48544000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48206000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-329000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1399000 USD
CY2011Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
245000 USD
CY2011Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
22711000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
44287000 USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
49000 USD
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
62625000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1662321 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1662321 shares
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
1480000 USD
CY2011Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2054000 USD
CY2011Q4 us-gaap Assets
Assets
53730000 USD
CY2011Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11763000 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
232000 USD
CY2011Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
6775000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18770000 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
465000 USD
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
144000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
49399000 USD
CY2012Q4 us-gaap Defined Benefit Plan Current Assets
DefinedBenefitPlanCurrentAssets
279000 USD
CY2011Q4 us-gaap Defined Benefit Plan Current Assets
DefinedBenefitPlanCurrentAssets
245000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55000 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49362000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39971000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
9443000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53730000 USD
CY2010 us-gaap Sales Revenue Net
SalesRevenueNet
106000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1310000 USD
CY2011 us-gaap Sales Revenue Net
SalesRevenueNet
803000 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
683000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
49625000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
49000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
49000000 shares
CY2011Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
69520000 USD
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35149000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30627000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23517000 USD
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5080000 USD
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7928000 USD
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20132000 USD
CY2010 us-gaap Costs And Expenses
CostsAndExpenses
40229000 USD
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
38555000 USD
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
43649000 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-40123000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-37752000 USD
CY2012 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.72
CY2011 us-gaap Net Income Loss
NetIncomeLoss
53815000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-46284000 USD
CY2010 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3430000 USD
CY2011 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3430000 USD
CY2012 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1143000 USD
CY2010 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41893000 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
50385000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47427000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-42169000 USD
CY2010 us-gaap Investment Income Interest
InvestmentIncomeInterest
107000 USD
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
120000 USD
CY2011 us-gaap Interest Expense
InterestExpense
1866000 USD
CY2012 us-gaap Interest Expense
InterestExpense
3575000 USD
CY2010 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
542000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
117000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-660000 USD
CY2010 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
649000 USD
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1718000 USD
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4115000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39474000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39470000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46284000 USD
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-399000 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16245000 USD
CY2010 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39075000 USD
CY2011 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23225000 USD
CY2012 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-46284000 USD
CY2010 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
612000 USD
CY2011 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
2188000 USD
CY2011 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
74852000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
612000 USD
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
77040000 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-38463000 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Use of Estimates</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">The preparation of the financial statements in accordance with U.S.&#160;GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair value of assets, convertible preferred stock and common stock, stock options and warrants, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions, including information received from its service providers and independent valuation consultants, which it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p></div>
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Concentration of Credit Risk</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and marketable securities. The counterparties are various corporations and financial institutions of high credit standing.</font></p> <p style="FONT-FAMILY: times"><font size="2">Substantially all of the Company's cash and cash equivalents are maintained with well known, U.S. and non U.S. financial institutions and corporations. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, management believes they bear minimal risk.</font></p></div>
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
912000 USD
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
251000 USD
CY2010 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2000 USD
CY2011 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2012 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-58000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38465000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53816000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46342000 USD
CY2010 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
54000 USD
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
25000 USD
CY2011 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-85000 USD
CY2012 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-710000 USD
CY2010 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
2000 USD
CY2011 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
-1000 USD
CY2012 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
57000 USD
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1188000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
879000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
871000 USD
CY2011 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
218000 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-74000 USD
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26870000 USD
CY2012 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
330000 USD
CY2011Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
697000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
65000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30621869 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30621869 shares
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
297000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
-82000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
443000 USD
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-284000 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-44000 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11000 USD
CY2010 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-220000 USD
CY2011 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-114000 USD
CY2012 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
664000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
247000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
516000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5211000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-959000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1098000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
697000 USD
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
120000 USD
CY2010 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
64000 USD
CY2011 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
539000 USD
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
109000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32192000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38206000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47199000 USD
CY2010 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-352000 USD
CY2011 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
2021000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32544000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36185000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47199000 USD
CY2010 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32781000 USD
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17890000 USD
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
97674000 USD
CY2010 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
58898000 USD
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49468000 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
685000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
753000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
25823000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8295000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-48959000 USD
CY2011 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
25607000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25823000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33902000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48959000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1509000 USD
CY2011 us-gaap Interest Paid
InterestPaid
1412000 USD
CY2012Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
279000 USD
CY2012 us-gaap Interest Paid
InterestPaid
2938000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23740000 USD
CY2010 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000 USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
11088000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
36419000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22983000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
309000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24804000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8242000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29000 USD
CY2011 us-gaap Proceeds From Secured Notes Payable
ProceedsFromSecuredNotesPayable
30000000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40302000 USD
CY2012Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
144000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
91741000 USD
CY2012 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
6775000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11000 USD
CY2010 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1345000 USD
CY2011 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
975000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
55000 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
89000 USD
CY2012Q4 us-gaap Assets
Assets
93989000 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10666000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
508000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
11809000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
31000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
143851000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-57000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86255000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
57570000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93989000 USD
CY2012 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6044000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1341000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29054000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
87916000 USD
CY2010 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
397000 USD
CY2011 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-1967000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-944000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27087000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87916000 USD
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7665000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31405000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-44320000 USD
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
-6156000 USD
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000 USD
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
265000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-82000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
443000 USD
CY2010 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000 USD
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000 USD
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-58000 USD
CY2010 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0 USD
CY2011Q4 supn Subsidiary Or Equity Method Investee Percentage Of Equity Interest Sold
SubsidiaryOrEquityMethodInvesteePercentageOfEquityInterestSold
1.00 pure
CY2012 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 item
CY2012 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2012 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
1100000 USD
CY2012 supn Finite Lived Intangible Assets Estimated Annual Aggregate Amortization Expense
FiniteLivedIntangibleAssetsEstimatedAnnualAggregateAmortizationExpense
229000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11809000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10847000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
569000 USD
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
23225000 USD
CY2011 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
800000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5746000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4436000 USD
CY2010 us-gaap Depreciation
Depreciation
959000 USD
CY2011 us-gaap Depreciation
Depreciation
650000 USD
CY2011 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2292000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2292000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1609000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1380000 USD
CY2010 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
229000 USD
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
229000 USD
CY2012 supn Operating Leases Base Annual Rent Increase Percentage
OperatingLeasesBaseAnnualRentIncreasePercentage
0.02 pure
CY2012 supn Operating Leases Optional Lease Extension Period
OperatingLeasesOptionalLeaseExtensionPeriod
P5Y
CY2012 supn Operating Leases Additional Allowance For Tenant And Capital Improvement
OperatingLeasesAdditionalAllowanceForTenantAndCapitalImprovement
2400000 USD
CY2010 supn Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
900000 USD
CY2011 supn Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
1400000 USD
CY2012 supn Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
1700000 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
906000 USD
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
918000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
906000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
966000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
985000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1004000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1025000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1399000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5379000 USD
CY2012 supn Defined Contribution Plan Eligibility Minimum Age
DefinedContributionPlanEligibilityMinimumAge
P21Y
CY2012 supn Defined Contribution Plan Maximum Employee Contribution Percentage
DefinedContributionPlanMaximumEmployeeContributionPercentage
0.90 pure
CY2012 supn Defined Contribution Plan Percentage Vesting Of Employee Contribution
DefinedContributionPlanPercentageVestingOfEmployeeContribution
1.00 pure
CY2012 supn Defined Contribution Plan Employer Match Level One
DefinedContributionPlanEmployerMatchLevelOne
1.00 pure
CY2012 supn Defined Contribution Plan Employer Match Employee Contribution Level One
DefinedContributionPlanEmployerMatchEmployeeContributionLevelOne
0.03 pure
CY2012 supn Defined Contribution Plan Employer Match Level Two
DefinedContributionPlanEmployerMatchLevelTwo
0.50 pure
CY2012 supn Employer Match Employee Contribution Level Two
EmployerMatchEmployeeContributionLevelTwo
0.02 pure
CY2012 supn Defined Contribution Plan Maximum Discretionary Employer Contribution Percentage
DefinedContributionPlanMaximumDiscretionaryEmployerContributionPercentage
0.60 pure
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
323000 USD
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
254000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
267000 USD
CY2012Q2 dei Entity Public Float
EntityPublicFloat
19554538 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
297000 USD
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <p style="FONT-FAMILY: times"><font size="2"><b>1. Organization and Nature of Operations</b></font></p> <p style="FONT-FAMILY: times"><font size="2">Supernus Pharmaceuticals,&#160;Inc. (the Company) was incorporated in Delaware on March&#160;30, 2005, and commenced operations on December&#160;22, 2005. The Company is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company has two proprietary products and several proprietary product candidates in clinical development that address the epilepsy and attention deficit hyperactivity disorder markets.</font></p> <p style="FONT-FAMILY: times"><font size="2">The Company is currently focused on the commercialization of Oxtellar XR (formerly known as SPN-804) and the anticipated commercialization of Trokendi XR (formerly known as SPN-538). Oxtellar XR received final approval from the Food and Drug Administration (FDA) on October&#160;19, 2012 and the Company began the commercial launch of this product on February&#160;4, 2013. Accordingly, the Company had not yet generated any revenues from product sales through December&#160;31, 2012. In addition, Trokendi XR received tentative approval from the FDA on June&#160;25, 2012. Except for profits earned in 2009 and 2011 due to non-recurring transactions, the Company has incurred net losses from operations since its inception. The Company had net (loss) income of approximately $(38.5) million, $53.8&#160;million, and $(46.3) million during the years ended December&#160;31, 2010, 2011 and 2012, respectively. The net income in 2011 was primarily due to a gain on the sale of TCD Royalty Sub&#160;LLC (TCD) of approximately $74.9&#160;million, net of taxes, being reported as discontinued operations (see Note&#160;10). The Company has financed its operations primarily through the sale of equity securities, issuance of debt instruments, and amounts received under its royalty and development agreements. Management expects operating losses to continue for the foreseeable future until one or more of its products are established in the marketplace. The Company will need to obtain additional capital through equity offerings, debt financings and/or payments under new or existing licensing and research and development collaboration agreements (see Note&#160;2).</font></p> <p style="FONT-FAMILY: times"><font size="2">The Company's operations are subject to certain risks and uncertainties. The risks include the success of our product launches, receipt of final FDA approval for Trokendi XR, negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, more stringent regulatory environment, the need to retain key personnel and protect intellectual property, product liability, and the availability of additional capital financing on terms acceptable to the Company.</font></p></div>
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
18754000 USD
CY2010 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-399000 USD
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-14090000 USD
CY2010 us-gaap Income Tax Expense Benefit Continuing Operations
IncomeTaxExpenseBenefitContinuingOperations
-399000 USD
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-2155000 USD
CY2011 us-gaap Income Tax Expense Benefit Continuing Operations
IncomeTaxExpenseBenefitContinuingOperations
-16245000 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13421000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13419000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16270000 USD
CY2010 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
61000 USD
CY2012 supn Revision Of Commercial Plan Number Of Late Stage Epilepsy Product Candidates
RevisionOfCommercialPlanNumberOfLateStageEpilepsyProductCandidates
2 item
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92382000 USD
CY2012Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
664000 USD
CY2012 supn Number Of Product Candidates Receiving Tentative Approval
NumberOfProductCandidatesReceivingTentativeApproval
1 item
CY2012 supn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
29000 USD
CY2010 supn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4000 USD
CY2011 supn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
29000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17700000 USD
CY2012 supn Common Stock Conversion Ratio Of Reverse Stock Split
CommonStockConversionRatioOfReverseStockSplit
0.25 pure
CY2010 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-26.77
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.39
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-26.38
CY2011 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-16.60
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
47.99
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
31.39
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.72
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6499000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5078000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000 USD
CY2012 us-gaap Depreciation
Depreciation
642000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
339000 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
229000 USD
CY2012 supn Period Subsequent To Expiry Date For Accepting Damaged Or Defective Product
PeriodSubsequentToExpiryDateForAcceptingDamagedOrDefectiveProduct
P12M
CY2012Q4 supn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3335000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1820000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7860000 USD
CY2012Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
1152000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
1152000 USD
CY2011Q4 supn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
6501000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1089000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9275000 USD
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
208000 USD
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
91000 USD
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
91000 USD
CY2012Q4 us-gaap Sales Revenue Net
SalesRevenueNet
1090000 USD
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
8086000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
9348000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
12381000 USD
CY2012Q4 us-gaap Costs And Expenses
CostsAndExpenses
13834000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-9277000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-10013000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-13482000 USD
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-13512000 USD
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.05
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2012Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10013000 USD
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2012Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-9277000 USD
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1563000 USD
CY2011Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
417000 USD
CY2011Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
76394000 USD
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-11049000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-7377000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-9734000 USD
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
81975000 USD
CY2012 supn Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
1156000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13482000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13512000 USD
CY2011Q2 us-gaap Sales Revenue Net
SalesRevenueNet
750000 USD
CY2011Q3 us-gaap Sales Revenue Net
SalesRevenueNet
11000 USD
CY2011Q4 us-gaap Sales Revenue Net
SalesRevenueNet
42000 USD
CY2011Q1 us-gaap Costs And Expenses
CostsAndExpenses
9198000 USD
CY2011Q2 us-gaap Costs And Expenses
CostsAndExpenses
9146000 USD
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
9926000 USD
CY2011Q4 us-gaap Costs And Expenses
CostsAndExpenses
10285000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-9715000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-8940000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10151000 USD
CY2011Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
5581000 USD
CY2011Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1334000 USD
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17440910 shares
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17440910 shares
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1605324 shares
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1605324 shares
CY2010 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1587968 shares
CY2010 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1587968 shares
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1152000 USD
CY2012 supn Number Of Proprietary Products In Clinical Development
NumberOfProprietaryProductsInClinicalDevelopment
2 item
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
466000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
983000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-82000 USD
CY2012 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
49000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2492000 USD
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
213000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1547000 USD
CY2011Q4 us-gaap Interest Payable Current
InterestPayableCurrent
138000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.64
CY2011Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.15
CY2011Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.90
CY2011Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.34
CY2011Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.84
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.98
CY2011Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.26
CY2011Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
37.80
CY2011Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.64
CY2011Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.15
CY2011Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.90
CY2011Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.88
CY2011Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.84
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.98
CY2011Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.26
CY2011Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
46.64

Files In Submission

Name View Source Status
0001047469-13-002844-index-headers.html Edgar Link pending
0001047469-13-002844-index.html Edgar Link pending
0001047469-13-002844.txt Edgar Link pending
0001047469-13-002844-xbrl.zip Edgar Link pending
a2213534z10-k.htm Edgar Link pending
a2213534zex-10_33.htm Edgar Link pending
a2213534zex-10_34.htm Edgar Link pending
a2213534zex-14.htm Edgar Link pending
a2213534zex-23.htm Edgar Link pending
a2213534zex-31_1.htm Edgar Link pending
a2213534zex-31_2.htm Edgar Link pending
a2213534zex-32_1.htm Edgar Link pending
a2213534zex-32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g208286.jpg Edgar Link pending
g293475.jpg Edgar Link pending
g326815.jpg Edgar Link pending
g448133.jpg Edgar Link pending
g598180.jpg Edgar Link pending
g68020.jpg Edgar Link pending
g705799.jpg Edgar Link pending
g911747.jpg Edgar Link pending
g920041.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20121231.xml Edgar Link completed
supn-20121231.xsd Edgar Link pending
supn-20121231_cal.xml Edgar Link unprocessable
supn-20121231_def.xml Edgar Link unprocessable
supn-20121231_lab.xml Edgar Link unprocessable
supn-20121231_pre.xml Edgar Link unprocessable